{{multiple issues|
{{expand|time=2017-12-24T17:39:18+00:00}}
{{no footnotes|time=2017-12-24T17:39:18+00:00}}
{{refimprove|time=2017-12-24T17:39:18+00:00}}
}}
{{Drugbox
| verifiedrevid = 464189825
| IUPAC_name = ''N''-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)<br>quinazolin-4-amine
| image = Erlotinib Structural Formulae.png
| width = 250
| image2 = Erlotinib-1m17-3D-balls.png

<!--Clinical data-->
| tradename = Tarceva
| Drugs.com = {{drugs.com|monograph|erlotinib}}
| MedlinePlus = a605008
| licence_EU = Tarceva
| licence_US = Erlotinib
| pregnancy_US = D
| legal_UK = POM
| legal_US = Rx-only
| routes_of_administration = Oral [[Tablet_(pharmacy)|tablets]]

<!--Pharmacokinetic data-->
| bioavailability = 59%
| protein_bound = 95%
| metabolism = [[Liver|Hepatic]] (mainly [[CYP3A4|CYP3A4]],  less [[CYP1A2|CYP1A2]])
| elimination_half-life = 36.2 hrs ([[median|median]])
| excretion = >98% as metabolites, of which >90% via [[faeces|faeces]], 9% via [[urine|urine]]

<!--Identifiers-->
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 183321-74-6
| ATC_prefix = L01
| ATC_suffix = XE03
| PubChem = 176870
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
 | DrugBank = DB00530
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 154044
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = J4T82NDH7E
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07907
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 114785
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 553

<!--Chemical data-->
| C=22 | H=23 | N=3 | O=4
| molecular_weight = 393.436 g/mol
| smiles = COCCOc1cc2c(cc1OCCOC)ncnc2Nc3cccc(c3)C#C
| InChI = 1/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)
| InChIKey = AAKJLRGGTJKAMG-UHFFFAOYAM
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = AAKJLRGGTJKAMG-UHFFFAOYSA-N
}}

'''厄洛替尼'''（{{lang-en|Erlotinib}}，商品名：Tarceva，'''特罗凯'''）是用于治疗{{le|非小细胞肺癌|Non-small-cell lung carcinoma}}（NSCLC）、[[胰腺癌|胰腺癌]]等几种癌症的药物，作为一种[[酪氨酸激酶抑制剂|酪氨酸激酶抑制剂]]作用于[[表皮生长因子受体|表皮生长因子受体]]，由[[罗氏|罗氏]]公司生产。
<!--这些文字哪里来的？
两项多中心、随机、安慰剂对照的Ⅲ期试验中，结果显示厄洛替尼联合含铂化疗方案（卡铂+紫杉醇；或者吉西他滨+顺铂）作为局部晚期或转移的NSCLC 患者一线治疗，相对单用含铂化疗未增加临床获益，因此不推荐用于上述情况的一线治疗。厄洛替尼单药可用于经4 个周期以铂类为基础的一线化疗后处于疾病稳定的局部晚期或转移的非小细胞肺癌患者的维持治疗。该适应症是基于一项随机、双盲、安慰剂对照研究（BO18192）结果[见【临床试验】]。目前尚未获得比较一线化疗后未进展和进展后使用厄洛替尼治疗的临床研究数据。本品用于EGFR 突变人群一线治疗的临床研究正在进行中。建议经治医生根据本品和同类药物研究进展以及患者自身状况综合考虑适宜的治疗选择。
-->
==藥物合成==
*第一種合成路徑
[[File:Erlotinib_Synthesis.svg|900px]]
*第二種合成路徑
[[File:Erlotinib_synthesis-2.svg|850px]]
==参考文献==
{{reflist}}
==外部链接==
*[http://www.tarceva.com Official Tarceva website] {{Wayback|url=http://www.tarceva.com/ |date=20080907101941 }}
*[http://www.cancercompass.com/message-board/message/all,1804,0.htm Tarceva Discussion Group for Cancer Patients] {{Wayback|url=http://www.cancercompass.com/message-board/message/all,1804,0.htm |date=20200610220343 }}
*{{cite journal | pmid = 15284455 | doi=10.1126/science.1101637 | volume=305 | issue=5687 | title=Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways |date=August 2004 | journal=Science | pages=1163–7 | author=Sordella R, Bell DW, Haber DA, Settleman J}}.
* Genzyme "[https://web.archive.org/web/20060314180258/http://www.genzyme.com/corp/investors/GENZ%20PR-092705.asp Genzyme Launches Exclusive Lung Cancer Test]" Press Release September 27, 2005
* [http://jco.ascopubs.org/cgi/content/abstract/22/16/3238 "Determinants of Tumor Response and Survival With Erlotinib in Patients With Non-Small-Cell Lung Cancer] {{Wayback|url=http://jco.ascopubs.org/cgi/content/abstract/22/16/3238 |date=20090409005024 }}, ''Journal of Clinical Oncology'', August 15, 2004.
* [https://web.archive.org/web/20131113204417/http://www.stopsmokingdoctors.com/pdf/Lung_Cancer_Frontiers_Oct2003.pdf October 2003 issue of ''Lung Cancer Frontiers'' on rash/effectiveness correlation]
* [https://web.archive.org/web/20140707230038/http://cancergrace.org/lung/2011/02/21/faq-egfr-inhibitor-rash-assoc/''FAQ: I started an EGFR inhibitor two weeks ago but haven’t developed a rash. Does this mean it’s not working?''], Dr. Howard L. (Jack) West, M.D., ''[http://cancergrace.org GRACE]{{Wayback|url=http://cancergrace.org/lung/2011/02/21/faq-egfr-inhibitor-rash-assoc/ |date=20140707230038 }}'', February 21, 2011 (directed toward the layperson).
*http://www.cancer.gov/clinicaltrials/results/lung-and-erlotinib0604l{{dead link|date=2017年12月 |bot=InternetArchiveBot |fix-attempted=yes }}
*https://web.archive.org/web/20081012081613/http://www.roche.com/med-cor-2007-10-22
*https://web.archive.org/web/20110726060413/http://www.roche.com/med-cor-2009-05-30b
*https://web.archive.org/web/20120918193637/http://www.cipla.com/whatsnew/news.htm#27apr09
*https://web.archive.org/web/20120918193637/http://www.cipla.com/whatsnew/news.htm#20mar08
{{Extracellular chemotherapeutic agents}}